Patient populations and interventions in VTE treatment
| Initial management: up through the first week |
| Home treatment vs hospital treatment for patients with uncomplicated DVT |
| Home treatment vs hospital treatment for patients with PE and low risk for complication |
| DOAC vs VKA for patients with VTE |
| One DOAC vs another DOAC for patients with VTE |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with extensive proximal DVT |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with PE and hemodynamic compromise |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with submassive PE |
| Catheter-directed thrombolysis vs systemic thrombolysis for patients with DVT |
| Catheter-directed thrombolysis vs systemic thrombolysis for patients with PE |
| IVC filter plus anticoagulation vs anticoagulation alone for patients with DVT and significant cardiopulmonary disease |
| IVC filter plus anticoagulation vs anticoagulation alone for patients with PE and hemodynamic compromise |
| Primary treatment: treatment of the acute event |
| Longer course of anticoagulation vs shorter course for patients with VTE related to a transient risk factor |
| Longer course of anticoagulation vs shorter course for patients with VTE related to a chronic risk factor |
| Longer course of anticoagulation vs shorter course for patients with unprovoked VTE |
| Secondary prevention: continuation of anticoagulation after primary treatment |
| Prognostic scores vs no prognostic score to decide duration of treatment for patients with unprovoked VTE |
| D-dimer vs no D-dimer to decide duration of treatment for patients with unprovoked VTE |
| Ultrasound vs no ultrasound to decide duration of treatment for patients with unprovoked VTE |
| Indefinite anticoagulation vs discontinuation for patients with VTE related to a chronic risk factor |
| Indefinite anticoagulation vs discontinuation for patients with unprovoked VTE |
| Aspirin vs anticoagulation for patients with VTE who are going to continue antithrombotic therapy |
| Lower-target INR vs standard target for patients with VTE who are going to continue on anticoagulation |
| Lower-dose DOAC vs standard-dose DOAC for patients with VTE who are going to continue on anticoagulation |
| Treatment of recurrent events |
| DOAC vs LMWH for patients with breakthrough VTE during treatment with VKA |
| Indefinite anticoagulation vs discontinuation for patients with recurrent VTE related to a transient risk factor |
| Indefinite anticoagulation vs discontinuation for patients with recurrent unprovoked VTE |
| Additional management issues |
| Continuation of aspirin vs discontinuation for patients with VTE who initiate anticoagulation |
| Compression stockings plus anticoagulation vs anticoagulation alone for patients with DVT |
| Compression stockings plus anticoagulation vs anticoagulation alone for patients with DVT and high risk for PTS |
| Excluded questions and reason for exclusion |
| Anticoagulation vs no anticoagulation for patients with CVC-associated DVT (addressed in future guideline document from ASH) |
| Removal of CVC vs maintaining CVC for patients with CVC-associated DVT (addressed in future guideline document from ASH) |
| Anticoagulation vs no anticoagulation for patients with incidental PE (addressed in future guideline document from ASH) |
| One DOAC vs another DOAC for patients with VTE during treatment with VKA (already addressed by related question above, “One DOAC vs another DOAC for patients with VTE”) |
| Initial management: up through the first week |
| Home treatment vs hospital treatment for patients with uncomplicated DVT |
| Home treatment vs hospital treatment for patients with PE and low risk for complication |
| DOAC vs VKA for patients with VTE |
| One DOAC vs another DOAC for patients with VTE |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with extensive proximal DVT |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with PE and hemodynamic compromise |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with submassive PE |
| Catheter-directed thrombolysis vs systemic thrombolysis for patients with DVT |
| Catheter-directed thrombolysis vs systemic thrombolysis for patients with PE |
| IVC filter plus anticoagulation vs anticoagulation alone for patients with DVT and significant cardiopulmonary disease |
| IVC filter plus anticoagulation vs anticoagulation alone for patients with PE and hemodynamic compromise |
| Primary treatment: treatment of the acute event |
| Longer course of anticoagulation vs shorter course for patients with VTE related to a transient risk factor |
| Longer course of anticoagulation vs shorter course for patients with VTE related to a chronic risk factor |
| Longer course of anticoagulation vs shorter course for patients with unprovoked VTE |
| Secondary prevention: continuation of anticoagulation after primary treatment |
| Prognostic scores vs no prognostic score to decide duration of treatment for patients with unprovoked VTE |
| D-dimer vs no D-dimer to decide duration of treatment for patients with unprovoked VTE |
| Ultrasound vs no ultrasound to decide duration of treatment for patients with unprovoked VTE |
| Indefinite anticoagulation vs discontinuation for patients with VTE related to a chronic risk factor |
| Indefinite anticoagulation vs discontinuation for patients with unprovoked VTE |
| Aspirin vs anticoagulation for patients with VTE who are going to continue antithrombotic therapy |
| Lower-target INR vs standard target for patients with VTE who are going to continue on anticoagulation |
| Lower-dose DOAC vs standard-dose DOAC for patients with VTE who are going to continue on anticoagulation |
| Treatment of recurrent events |
| DOAC vs LMWH for patients with breakthrough VTE during treatment with VKA |
| Indefinite anticoagulation vs discontinuation for patients with recurrent VTE related to a transient risk factor |
| Indefinite anticoagulation vs discontinuation for patients with recurrent unprovoked VTE |
| Additional management issues |
| Continuation of aspirin vs discontinuation for patients with VTE who initiate anticoagulation |
| Compression stockings plus anticoagulation vs anticoagulation alone for patients with DVT |
| Compression stockings plus anticoagulation vs anticoagulation alone for patients with DVT and high risk for PTS |
| Excluded questions and reason for exclusion |
| Anticoagulation vs no anticoagulation for patients with CVC-associated DVT (addressed in future guideline document from ASH) |
| Removal of CVC vs maintaining CVC for patients with CVC-associated DVT (addressed in future guideline document from ASH) |
| Anticoagulation vs no anticoagulation for patients with incidental PE (addressed in future guideline document from ASH) |
| One DOAC vs another DOAC for patients with VTE during treatment with VKA (already addressed by related question above, “One DOAC vs another DOAC for patients with VTE”) |
CVC, central venous catheter.